{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:48Z","timestamp":1793661048408,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["2.0"],"award-info":[{"award-number":["2.0"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006696","name":"Fondazione Guido Berlucchi","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/501100006696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ygyno.2022.11.014","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:08:06Z","timestamp":1669414086000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Justin","family":"Harold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego D.","family":"Manavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zipponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang-Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Skyler","family":"Verzosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.11.014_bb0005","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical management of uterine sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0015","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Gynecologic oncology group (GOG) study, phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a gynecologic oncology group (GOG) study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0025","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study","volume":"3","author":"Omura","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0030","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.11.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","author":"Abeshouse","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2022.11.014_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005850","article-title":"Exome sequencing of uterine Leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12","volume":"12","author":"M\u00e4kinen","year":"2016","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"PNAS."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/genes7090066","article-title":"The role of ATRX in the alternative lengthening of telomeres (ALT) phenotype","volume":"7","author":"Amorim","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ygyno.2022.11.014_bb0055","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2022.11.014_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026567","article-title":"ATRX and DAXX: mechanisms and mutations","volume":"7","author":"Dyer","year":"2017","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0070","first-page":"2072","article-title":"Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma","volume":"7","author":"Yang","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0085","doi-asserted-by":"crossref","first-page":"32280","DOI":"10.1038\/srep32280","article-title":"Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX","volume":"6","author":"Hu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0090","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0095","article-title":"SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma, NAR","volume":"2","author":"Kurashima","year":"2020","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0100","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-20-1744","article-title":"BRG1 loss predisposes lung cancers to replicative stress and ATR dependency","volume":"80","author":"Gupta","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0105","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-21-0433","article-title":"SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy","author":"Mardinian","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2022.11.014_bb0110","author":"Bayer"},{"key":"10.1016\/j.ygyno.2022.11.014_bb0115","author":"National Cancer Institute (NCI)"}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2023.01.029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582201928X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582201928X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:00:04Z","timestamp":1688994004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582201928X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"alternative-id":["S009082582201928X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.014","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ygyno.2023.01.029","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}